These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1646700)

  • 21. In vivo sequential selection of Escherichia coli with topoisomerase- and efflux-mediated misleading quinolone resistance phenotypes.
    Smati M; Emond JP; Arlet G; Tankovic J
    Microb Drug Resist; 2012 Feb; 18(1):19-22. PubMed ID: 22043806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacterial resistance to quinolones: mechanisms and clinical importance.
    Wolfson JS; Hooper DC
    Rev Infect Dis; 1989; 11 Suppl 5():S960-8. PubMed ID: 2549610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quinolone uptake by bacteria and bacterial killing.
    Diver JM
    Rev Infect Dis; 1989; 11 Suppl 5():S941-6. PubMed ID: 2549609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China.
    Tanaka M; Zhang YX; Ishida H; Akasaka T; Sato K; Hayakawa I
    J Med Microbiol; 1995 Mar; 42(3):214-9. PubMed ID: 7884804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
    Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
    Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usual and unusual antibacterial effects of quinolones.
    Furet YX; Pechère JC
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():7-15. PubMed ID: 2175306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR; Malik M; Snyder M; Drlica K
    J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-Quinolone interactions with gyrase subunit B inhibitors.
    Lewin CS; Howard BM; Smith JT
    J Med Microbiol; 1991 Dec; 35(6):358-62. PubMed ID: 1661337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ofloxacin as the standard 4-quinolone in sensitivity tests.
    Amyes SG; Paton RH; Miles RS; Hood J
    J Antimicrob Chemother; 1992 Jul; 30(1):101-2. PubMed ID: 1429327
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antimicrobial activity and action mechanism of ofloxacin].
    Padeĭskaia EN
    Antibiot Khimioter; 1996; 41(9):13-23. PubMed ID: 9005780
    [No Abstract]   [Full Text] [Related]  

  • 31. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of quinolones against slowly growing bacteria.
    Dalhoff A; Matutat S; Ullmann U
    Chemotherapy; 1995; 41(2):92-9. PubMed ID: 7758362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
    Howard BM; Pinney RJ; Smith JT
    Microbios; 1994; 77(311):121-31. PubMed ID: 8152392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanisms for the development of quinolone resistance].
    Kojima M
    Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
    Tuchiluş C; Poiată A; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):383-6. PubMed ID: 16607805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.
    Fujimoto T; Mitsuhashi S
    Chemotherapy; 1990; 36(4):268-76. PubMed ID: 2174762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1996 Mar; 49(3):264-72. PubMed ID: 8935122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.